Covid vaccination cut risk of adverse heart events, large study finds
Updated COVID-19 vaccines continue to reduce major cardiovascular risks—including strokes, heart attacks, and heart-related hospitalizations—by up to 40% in vaccinated individuals, according to new research. Benefits persist even with newer formulations, though rare heart toxicity risks remain a caution. The findings reinforce prior studies showing vaccination lowers adverse cardiac events by up to 24%, particularly in older adults. Experts maintain the vaccines’ overall cardiovascular protection outweighs risks for most eligible groups.
What changed
New data shows a broader 40% reduction in major heart events linked to COVID-19, expanding beyond previous estimates of up to 24% for adverse cardiac outcomes.
Live updates
-
COVID vaccines cut heart risks by up to 40% in new study, experts say
confidence 93%Updated COVID-19 vaccines continue to reduce major cardiovascular risks—including strokes, heart attacks, and heart-related hospitalizations—by up to 40% in vaccinated individuals, according to new research. Benefits persist even with newer formulations, though rare heart toxicity risks remain a caution. The findings reinforce prior studies showing vaccination lowers adverse cardiac events by up to 24%, particularly in older adults. Experts maintain the vaccines’ overall cardiovascular protection outweighs risks for most eligible groups.
What's confirmed:
- Updated COVID-19 vaccines reduce the risk of major cardiovascular events—such as strokes, heart attacks, and hospitalization from heart disease—by about 40% in vaccinated individuals.
- Vaccination continues to offer substantial protection against adverse cardiac events, including heart attacks and cardiac death, even with the latest vaccine formulations.
- The cardiovascular benefits of COVID-19 vaccination persist for at least three months after infection, reducing mortality and major heart risks.
- Despite FDA warnings about rare heart toxicity risks, the overall reduction in adverse cardiac events supports vaccination as the recommended course for eligible age groups.
-
COVID vaccines linked to lower heart risks in new studies; FDA warnings persist
confidence 93%Multiple studies confirm COVID-19 vaccination reduces adverse cardiac events, including heart attacks and cardiac death, by up to 24% in vaccinated adults. A VA study of over 1 million patients found continued protection from updated 2024-2025 vaccines, especially in older adults. Despite FDA warnings about rare heart toxicity risks, vaccination remains recommended for eligible ages as benefits outweigh risks for most. New research also shows vaccination cuts major cardiovascular risks and mortality post-infection for up to three months.
What's confirmed:
- COVID-19 vaccination is associated with a nearly 24% reduction in all-cause cardiac events, including heart attacks and cardiac death, in adults.
- A VA study of over 1 million patients found the 2024-2025 COVID vaccine continued to reduce major cardiovascular events, particularly in older adults.
- Vaccination provided a significant protective effect against major acute cardiovascular events (MACE) and all-cause mortality in individuals aged 40–85 after SARS-CoV-2 infection, with effects lasting up to three months post-infection.
- Three recent studies reinforce that COVID vaccination remains beneficial for adults despite declining vaccination rates in the U.S.
- The FDA has maintained warnings about rare heart toxicity risks linked to mRNA vaccines while recommending vaccination for all eligible ages.
Still unconfirmed:
- A *Nature* study suggests vaccination effects on cardiovascular risks persist for approximately three months after acute infection, though the exact duration may vary.
-
COVID vaccines tied to 24% lower cardiac risk in large study; FDA adds heart warnings
confidence 95%A study of over one million veterans found COVID-19 vaccination reduced all-cause cardiac events by nearly 24%, reinforcing broader cardiovascular protection. Meanwhile, the FDA has tightened warnings on mRNA vaccines regarding rare heart toxicity risks. Vaccination remains recommended for all eligible ages, with benefits outweighing risks for most individuals.
What's confirmed:
- COVID-19 vaccination was associated with a nearly 24% reduction in all-cause cardiac events in a study of over one million veterans.
- The cardiovascular benefits of COVID-19 vaccines extend beyond respiratory protection, according to a peer-reviewed study published in *JAMA Internal Medicine*.
- The FDA has instructed Pfizer and Moderna to add stronger warnings to vaccine labels about the risk of cardiotoxicity.
- COVID-19 vaccines remain effective at preventing serious illness, hospitalization, and death, with the CDC recommending vaccination for all ages 6 months and older.
- Vaccination is the safest strategy to avoid hospitalizations, long-term health outcomes, and death from COVID-19, per CDC guidance.
Still unconfirmed:
- Anti-vaccine rhetoric has driven down vaccination rates, despite continued benefits.